Eisai Co. Ltd: PharmaVitae Profile

Datamonitor, June 2010, Pages: 68

This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this title

- Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sector

- See how the loss of patent protection on Eisai's blockbuster products Aricept and AcipHex/Pariet will impact Rx performance over 2008-14

- Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively

Chapter 1 About this profile
PharmaVitae Explorer database

Chapter structure
Executive summary
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Sales data
Analyst consensus

Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2002-14
Financial performance, 2002-14
Eisai: PharmaVitae forecasts at a glance
Strategic insight
1) 2002-08: Impressive prescription revenue growth
2) M&A boosts prescription revenue ahead of generic competition to blockbuster duo
3) 2010-14: Life after Aricept and AcipHex?
Aricept and AcipHex/Pariet face generic competition beyond 2010
Launch portfolio unable to offset expiry declines
Further M&A on the horizon?
Operating margin remains robust despite revenue decline
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

Table of figures

Chapter 3 Quarterly news update
Latest prescription pharma product news
Q1 2010
Latest corporate news
Q1 2010
Future product milestones

Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Merger of Sakuragaoka Research Laboratory and Nihon Eisai
Acquisition of Morphotek
Acquisition of Sanko Junyaku
Acquisition of MGI Pharma
Current corporate structure
Pharmaceuticals business unit structure
Prescription pharmaceuticals
Diagnostics
Consumer healthcare

Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2002-14
Product analysis
Product analysis, 2002-08
Product analysis, 2008-14
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2008-14
Core analysis, 2008-14
Expiry analysis, 2008-14
Launch/core/expiry configuration, 2008-14
Molecule type analysis
Externalization analysis

Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
Operating cost ratio and profit margin analysis, 2008-14
Operating costs and profit analysis, 2008-14

Chapter 7 Appendix
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer

List of Tables
Table 1: Eisai - PharmaVitae forecasts at a glance
Table 2: Eisai future product milestones, 2009-11
Table 3: Eisai product portfolio overview ($m), 2002-08
Table 4: Eisai product portfolio overview ($m), 2008-14
Table 5: Eisai prescription pharmaceutical sales by therapy area ($m), 2008-14
Table 6: Eisai prescription pharmaceutical sales by geographic region ($m), 2008-14
Table 7: Eisai launch portfolio overview ($m), 2008-14
Table 8: Eisai core portfolio overview ($m), 2008-14
Table 9: Eisai expiry portfolio overview ($m), 2008-14
Table 10: Eisai prescription pharmaceutical sales by molecule type ($m), 2008-14
Table 11: Eisai prescription pharmaceutical sales by source ($m), 2008-14
Table 12: Total Eisai sales by business unit ($m), 2002-08
Table 13: Eisai operating revenue/cost analysis ($m), 2002-08
Table 14: Eisai operating cost ratio analysis (% of total revenues), 2002-08
Table 15: Eisai operating cost ratio analysis (% of total revenues), 2008-14
Table 16: Eisai operating revenue/cost analysis ($m), 2008-14
Table 17: Exchange rates, 2009

List of Figures
Figure 1: The PharmaVitae Explorer
Figure 2: Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
Figure 3: Eisai's financial performance ($m), 2002-14
Figure 4: Eisai SWOT analysis
Figure 5: Current corporate structure
Figure 6: Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
Figure 7: Key product sales ($m), 2002-14
Figure 8: Eisai key sales growth drivers and resistors ($m), 2002-08
Figure 9: Eisai key sales growth drivers and resistors ($m), 2008-14
Figure 10: Eisai prescription pharmaceutical sales by therapy area ($m), 2002-14
Figure 11: Eisai prescription pharmaceutical sales by geographic region ($m), 2002-14
Figure 12: Eisai launch/core/expiry configuration ($m), 2008-14
Figure 13: Eisai prescription pharmaceutical sales by molecule type ($m), 2002-14
Figure 14: Eisai prescription pharmaceutical sales by source ($m), 2002-14
Figure 15: Eisai operating revenue/cost analysis ($m), 2002-14

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Sports and Fitness Nutrition - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Homeland Security and Emergency Management Market, 2013–2018
• Aerospace and Defense Industry - Global Strategic Business Report
• Israel Life Sciences Market Analysis
• Distance Learning - Global Outlook
• Global Education Industry Forecast to 2016 - Focus on Emerging Markets